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Leprosy is a chronic infectious disease caused by 
Mycobacterium leprae, an acid-fast bacillus that pres-
ents a peculiar tropism for peripheral nerves and the 
skin. The prevalence of leprosy in the world has de-
clined since the introduction of the multidrug therapy 
recommended by the World Health Organization (WHO 
1982). However, leprosy is still a public health problem, 
especially in Brazil, where the number of new cases is 
high (37,610 cases in 2009) (WHO 2010).
Significant progress has been made in controlling lep-
rosy and reducing the burden of the disease; however, there 
is much that is still required to reduce the disease burden. 
Early case identification is one of the aims of leprosy 
control programs (Oskam et al. 2003, WHO 2009). Thus, 
controlled clinical trials conducted on household contacts 
(HHC) are of great importance for the detection of new 
disease cases (Foss et al. 1993, Goulart et al. 2008). With 
this idea in mind, we undertook the study of examining the 
anti-PGL-1 antibody levels in HHC of leprosy patients.
Leprosy diagnosis is based on clinical examination, 
bacterial index, histopathological findings (Ridley & 
Jopling 1966) and the serologic determination of anti-
bodies. The phenolic glycolipid antibody (PGL-1), as 
measured using an enzyme-linked immunosorbent assay 
(ELISA), is considered to be a relevant marker of leprosy 
activity (Burgess et al. 1988, Zenha et al. 2009, Frota et 
al. 2010). The PGL-1 fraction is part of the cell envelope 
of M. leprae and induces the production of the specific 
humoral response against PGL-1 detected in patient se-
rum (Hunter et al. 1982, Cho et al. 1983, Foss et al. 1993). 
When the antibody is present at high levels, it can be 
inferred that the infection is active, especially during the 
reactional episodes that constitute a very common com-
plication in the evolution of leprosy (Chin-A-Lein et al. 
1992, Goulart et al. 2002).
With the current emphasis on strategies leading to 
an early diagnosis of leprosy in the world (WHO 2009), 
we need laboratory markers to detect leprosy in patients 
during the early stages of the disease and to help reduce 
the disability and deformities caused by permanent nerve 
damage. Thus, the present cross-sectional clinical trial 
was conducted to analyse the serum titres of anti-PGL-1 
antibodies as an adjunct tool for early leprosy diagnosis 
among leprosy HHC.
Patients, MateRiaLs and Methods
Patients - The families of leprosy patients being treat-
ed at the Leprosy Clinics of the School of Medicine of Ri-
beirão Preto (HCRP), University of São Paulo, were re-
cruited. Those who agreed to participate in the study were 
rescheduled for a clinical examination (nerve thickness, 
cutaneous lesions and sensitivity) by an experienced ex-
aminer and for serum anti-PGL-1 measurement. Subjects 
were excluded if they presented with co-existing local or 
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A cross-sectional clinical trial in which the serum anti-phenolic �lycolipi� �anti-P��-�� antibo�ies were ana-
lyse� in househol� contacts �HHC� of patients with leprosy as an a�junct early leprosy �ia�nostic marker was 
con�ucte�. The families of 83 patients un�erwent clinical examination an� serum anti-P��� measurement usin� 
enzyme-linke� immunosorbent assay. �f 3�� HHC� �8 were contacts of lepromatous leprosy ����� 8� were con-
tacts of bor�erline lepromatous �B��� �8 were contacts of bor�erline �BB� leprosy� 54 were contacts of bor�erline 
tuberculoi� �BT�� 4� were contacts of tuberculoi� �TT� an� �� were contacts of in�eterminate �I� leprosy. Con-
san�uinity with the patients was �etermine� for �3� �7�.5%� HHC. �f those �3� contacts� �83 ha� linear consan-
�uinity. Forty-nine HHC ha� collateral consan�uinity. Fifty-ei�ht contacts ��8.�%� teste� positive for anti-P��� 
antibo�ies. The number of seropositive contacts base� on the clinical forms of the in�ex case was �7 ���.3%� for 
��� �5 ��5.�%� for B�� one ��.7%� for BB� �4 ��4.�%� for BT� three �5.�%� for TT an� ei�ht ��3.7%� for I. At the 
one year follow-up� two �3.4%� of these seropositive contacts ha� �evelope� BT leprosy. The results of the present 
stu�y in�icate that the serum anti-P��-� I�M antibo�y may be useful for evaluatin� anti�en exposure an� as a 
tool for an early leprosy �ia�nosis in HHC.
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systemic infection and/or any disease that could affect 
the peripheral nervous system such as diabetes mellitus 
and alcoholism. The trial was approved by the local Ethi-
cal Committee (HCRP 13.549/2005) and all subjects pro-
vided written informed consent to participate.
Serum antibo�y titres - Ninety-six-well polystyrene 
plates (Costar, Cambridge, USA) were coated with anti-
gen (PGL-1, kindly provided by Dr JS Spencer, Colorado 
University, USA) in sodium carbonate buffer (2 µg/mL), 
pH 9.6 and stored at 4ºC until used. The serum from 
each patient was diluted 1:100 in 15 mM Tris-Tween 
buffer containing 5% sheep serum, 10 µL were added to 
each well and the plate was incubated for 1 h at 37ºC in a 
humidified chamber. At the end of the hour, the samples 
were washed with 15 mM Tris-Tween buffer and anti-
human IgM beta-galactosidase conjugate (Sigma, USA) 
diluted 1:600 in 15 mM Tris-Tween buffer containing 
5% sheep serum. The plates were incubated at 37ºC for 
1 h. A fluorogenic substrate (10 µL 4-methylumbelliferyl 
beta-D-galactopyranoside) was then added to the sam-
ples and the material was incubated at 37ºC for 30 min. 
The plate was read with a multiscan ELISA reader. Sera 
samples with an absorbance at 450 nm greater than 0.028 
[the mean absorbance plus 3 standard deviations (SD) of 
40 healthy Brazilian control subjects] were considered 
positive. Each serum sample was tested in duplicate.
Follow-up - All HHC have received follow-up ex-
aminations at the Leprosy Clinics at six-month inter-
vals since 2005.
Statistical analysis - Odds ratios and a Fisher’s exact 
test were used to test for differences between the groups 
that presented anti-PGL-1 levels ≥ or < cut-off (positive 
and negative levels, respectively) with the aid of the Sta-
tistical Analysis System - SAS® 9.0 software (San Diego, 
Cary, NC, USA). Significance was set at p < 0.05.
ResuLts
Characteristics of the stu�y population - Eighty-three 
families agreed to participate in the study. Of these fami-
lies, 331 HHC were examined and 11 were diagnosed as 
leprosy patients: two patients presented lepromatous lep-
rosy (LL), four presented the tuberculoid form (TT) and 
five presented the indeterminate form (I). The final study 
population sample enrolled consisted of 320 HHC of lep-
rosy patients (130 men and 190 women, mean ± SD age 
27.01 ± 19.57 years, range 1-81 years). HHC were grouped 
according to anti-PGL-1 levels. The characteristics of the 
patients are listed in Table I. Among the 83 leprosy pa-
tients, 25 presented LL, 20 presented borderline leproma-
tous (BL), seven were borderline (BB), 16 were borderline 
tuberculoid (BT), nine were TT and six were I. 
Profile of HHC - Ninety-eight HHC were contacts of 
LL patients, 80 of BL patients, 28 of BB patients, 54 of 
BT patients, 40 of TT patients and 20 of I leprosy pa-
tients. Two-hundred-and-thirty-two HHC had some level 
of relationship, i.e., linear consanguinity with the index 
case in 183 contacts and collateral consanguinity in 49 
contacts. The other 88 HHC had an affinity relationship.
Serum antibo�y titres - Of the 320 contacts, 58 (18.1%) 
had positive anti-PGL-1 levels. The anti-PGL-1 sero-
positivity levels among the contacts based on the clini-
cal forms of the index case inside the household were 17 
(29.3%) for LL, 15 (25.9%) for BL, one (1.7%) for BB, 14 
(24.1%) for BT, three (5.2%) for TT and eight (13.7%) for 
I. Serum anti-PGL-1 IgM antibodies were higher among 
female HHC (35) than among male HHC (23) (Table II).
Follow-up - All of the HHC are being followed at 
six-month intervals at the Leprosy Clinics, especially 
the seropositive contacts. After one year of follow-up, 
two seropositive contacts with confirmed linear consan-
guinity developed BT leprosy.
disCussion
In the present study, we first evaluated HHC of lep-
rosy patients and detected 11 new leprosy cases (3.3% 
of the contacts) based on the clinical examination. The 
cases were later confirmed with histopathological exam-
ination and bacilloscopic index, emphasising the impor-
tance of examining HHC for an early diagnosis (5 cases 
of I) and for the detection of occult prevalence (2 cases of 
LL) in a non-endemic region, as the leprosy prevalence 
in Ribeirão Preto is 0.89/10,000 habitants in 2009 (SI-
NAN 2010). Similar results were reported by Cardona-
Castro et al. (2005), who detected two multibacillary 
(MB) leprosy cases among the HHC from a Colombian 
region considered to be in the post-elimination phase. 
Therefore, we emphasise that the evaluation of HHC is a 
useful tool for leprosy control not only in endemic areas, 
but also in non-endemic areas.
In the present study, in an attempt to improve early 
detection, the levels of anti-PGL-1 antibodies were as-
sessed in serum samples from HHC of leprosy patients, 
as an adjunct to the determination of antigen exposure. 
The median age was similar for both seropositive and 
seronegative cases. The proportion of anti-PGL-1-sero- 
positive HHC among the different clinical forms was dif- 
ferent from the proportion previously reported in some 
studies conducted in endemic areas (Gonzalez-Abreu et 
al. 1990, Ulrich et al. 1991, Cellona et al. 1993). Although 
these studies found no differences in seropositivity rates 
among HHC of MB and paucibacillary leprosy (PB) lep-
rosy patients, our results indicated a slight difference 
in serum anti-PGL-1 IgM seropositivity rates between 
HHC of MB leprosy patients (56.8%) and of PB leprosy 
patients (43.1%), especially when comparing I leprosy 
patients (14%) x LL leprosy patients (29%) (p = 0.03). 
Similar results were reported by Calado et al. (2005), 
Carbona-Castro et al. (2008) and Frota et al. (2010). The 
presence of serum antibodies suggests that the PGL-1 
antigen induced a humoral immune response, but these 
increased antibody concentrations apparently could 
not block M. leprae multiplication in the host (Kaplan 
& Chase 1980, Touw et al. 1982), as we found that two 
cases progressed to BT leprosy after one year of follow-
up of these seropositive contacts. 
The results suggest a useful role for the measure-
ment of serum M. leprae-specific anti-PGL-1 IgM 
antibodies. The measurement can be used as an easy, 
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TABLE I
Clinical data of the leprosy patients and their household contacts (HHC)
Variables
Index case
n = 83 (%)
HHC
n = 320 (%)
Gender
   Male 58 (69.8) 130 (40.6)
   Female 25 (30.1) 190 (59.4)
Age
   Mean (range) 51.46 ± 14.60 (9-75) 27.01 ± 19.57 (1-81)
Clinical classification HHC based on index case
   Indeterminate leprosy 6 (7.2) 20 (6.2)
   Tuberculoid leprosy 9 (10.8) 40 (12.5)
   Borderline tuberculoid 16 (19.2) 54 (16.8)
   Borderline leprosy 7 (8.4) 28 (8.7)
   Borderline lepromatous 20 (24) 80 (25)
   Lepromatous leprosy 25 (30.1) 98 (30.6)
Operational classification
   Paucibacillary leprosy 31 (37.3) 114 (35.6)
   Multibacillary leprosy 52 (62.6) 206 (64.4)
TABLE II
Clinical data and anti-glycolipid antibody (PGL-1) titres 
of the household contacts (HHC) of leprosy patients
Variables
HHC
n (%) Total
Odds-ratio
(95% CI) p value
Anti-PGL-1 < 0.03a Anti-PGL-1 ≥ 0.03a
Gender
   Male 107 (40.8) 23 (39.7) 130 1.155 (0.644-2.073) 0.72
   Female 155 (57.2) 35 (60.3) 190
Age
   Mean (range) 26.64 ± 19.23 (1-81) 28.06 ± 19.72 (1-81) - - -
Clinical classification of the index case
   Indeterminate leprosy 12 (4.5) 08 (13.7) 20 3.176 (1.127-8.953) 0.03
   Tuberculoid leprosy 37 (14.1) 03 (5.2) 40 0.386 (0.107-1.400)
   Borderline tuberculoid 40 (15.2) 14 (24.1) 54 1.549 (0.685-3.500)
   Borderline leprosy 27 (10.3) 01 (1.7) 28 0.367 (0.079-1.694)
   Borderline lepromatous 65 (24.8) 15 (25.9) 80 1.083 (0.503-2.331)
   Lepromatous leprosyb 81 (30.9) 17 (29.3) 98 -
Operational classification
   Paucibacillary leprosy 89 (34) 25 (43.1) 114 0.733 (0.410-1.312) 0.29
   Multibacillary leprosy 173 (66) 33 (56.9) 206
Relationship with the index case
   Consanguinityc 187 (70.6) 45 (81.8) 232 - 0.06
   Linear� 153 30 183 -
   Collateral 34 15 49 2.129 (1.039-4.363)
   Affinitye 78 (29.4) 10 (18.2) 88 0.817 (0.397-1.681)
a: cut-off; b: clinical form; c: relationship by blood; �: relationship used as reference for comparison between the others; e: rela-
tionship by marriage; CI: confidence interval.
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non-invasive and inexpensive adjunct method for the 
detection of leprosy in the population, as reported pre-
viously (Foss et al. 1993, Frota et al. 2010). In addition, 
the results suggest an important role for the measure-
ment of serum anti-PGL-1 antibodies as a method for 
detecting subclinical infection, especially in leprosy 
contacts with low or no resistance to M. leprae (Foss et 
al. 1993). As seropositivity for IgM anti-PGL-1 might 
be a risk factor for developing leprosy, the seropositive 
individuals should be monitored via clinical examina-
tion, determination of the immune response and bacte-
riologic state for leprosy detection (Douglas et al. 2004, 
Cardona-Castro et al. 2009), as was done with the HHC 
selected in the present study.
There are some risk factors for the development of 
leprosy, in addition to being a contact, such as clinical 
form of leprosy of the index case, the physical distance 
and the consanguinity (Richardus et al. 2005, Moet et al. 
2006). Consanguinity is the relationship between mem-
bers from the same family and it can be classified as 
linear and collateral. Linear consanguinity is the blood 
relationship that exists among persons, where one person 
is descended from the other and proceeds upwards in a 
direct ascending line, whereas collateral consanguinity 
is the relation subsisting among persons who are de-
scended from the same common ancestor, but not from 
each other. Affinity was considered to be a relationship 
by marriage. The importance of consanguinity for the 
development of anti-PGL-1 IgM antibodies should be 
emphasised as most of the contacts with positive anti-
PGL-1 titres (45/58) had a family history of leprosy. In 
addition, the two cases that developed BT leprosy had a 
confirmed linear consanguinity with the index case.
The results of this study indicate that in a low-preva-
lence area a high proportion of HHC of leprosy patients 
are at an increased risk of developing leprosy (Cardona-
Castro et al. 2005, 2008, Dessunti et al. 2008). In con-
clusion, the clinical evaluation and serum measurements 
of anti-PGL-1 IgM are useful for the evaluation of anti-
gen exposure. The follow-up of HHC with high levels 
of anti-PGL-1 IgM could facilitate the characterisation 
of those contacts who are at risk of developing leprosy, 
particularly in cases of linear consanguinity.
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